SHUTTLE PHARMACEUTICALS HOLD (SHPH)

Company Profile

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 4 full-time employees. The company went IPO on 2022-08-31. The company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). The company is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) were developed for use as a radiation sensitizer for rectal cancers after the Phase II brain tumor clinical trial was initiated. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.

Company Info

SHUTTLE PHARMACEUTICALS HOLD

401 Professional Drive, Suite 260

Gaithersburg MARYLAND

P: 12404034212

Employees: 4

Website: https://shuttlepharma.com/